Source comparison
What Research Protocols Show: Week 1 vs Week 4 Outcomes
The Garvan Institute's Phase II clinical trial. Published in 2007 and involving 300 obese participants over 12 weeks. Found zero statistically significant difference in body weight or fat mass between AOD-9604 and placebo groups at the week-one checkpoint. Dif
This comparison does not assign a generated winner or score.
- The Garvan Institute's Phase II clinical trial. Published in 2007 and involving 300 obese participants over 12 weeks. Found zero statistically significant difference in body weight or fat mass between AOD-9604 and placebo groups at the week-one checkpoint. Differences began to emerge at week four, with the peptide group showing 1.8 kg greater fat mass reduction than placebo by week 12. This isn't a peptide failure. It's how lipolysis works at scale. One week of elevated HSL activity in a 90 kg human might liberate 200–400 grams of stored triglycerides, but if half get re-stored due to low oxidative demand, the net change is 100–200 grams. Below the detection threshold of most body composition tools.
- Research using DEXA scans. The gold standard for body composition measurement. Consistently shows that subcutaneous fat thickness changes of less than 3–5 mm are within normal measurement error. AOD-9604 results after 1 week in controlled settings typically produce 0.5–1.5 mm reductions in localized fat depots, which DEXA cannot reliably distinguish from hydration fluctuation or inter-scan variability. By week four, cumulative reductions reach 4–7 mm in targeted areas like abdominal subcutaneous fat. Crossing the threshold where the change becomes statistically significant and reproducible across multiple scans.